title: [Membrane-receptor disorders in adrenergic and histaminergic systems under peroxide exposure in bronchial asthma patients].
abstract: OBJECTIVE
  To characterize membrane-receptor peculiarities in adrenergic and histaminergic systems under model peroxide effect in bronchial asthma (BA).
  
  
  METHODS
  172 patients with BA, 17 patients with nonpulmonary allergy, 38 healthy men and 19 healthy blood relatives of BA patients were examined for peroxide resistance of erythrocytic membrane to modulation with adrenergic and histaminergic agonists and antagonists. The modified method by A. A. Abramov and A. A. Pokrovsky was used.
  
  
  RESULTS
  In atopic BA the phenomenon of inversion of the effect of beta-adrenoblocker (obzidan) and of combined effect of histamine and H1-antagonist (dimedrol) was revealed. The same phenomenon was registered at the stage of preasthma and at the preclinical stage of BA. In infection-dependent BA this phenomenon occurred less frequently being rare in remission. In both BA variants the shift of H1/H2-histaminergic balance to increased H1-activity exists which is more significant in atopic BA, preasthma and preclinical BA.
  
  
  CONCLUSIONS
  Peroxide effects modelled on red cell membranes enabled to characterize reactivity of adrenergic and histaminergic systems not only in BA but also in preasthma and preclinical BA.
authors.forename: V N
authors.initials: VN
authors.lastname: Mineev
authors.forename: I I
authors.initials: II
authors.lastname: Nesterovich
authors.forename: V V
authors.initials: VV
authors.lastname: Ivanova
mesh_terms: D000322:Adrenergic Agonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001249:Asthma / Q000097:blood* / Q000175:diagnosis; D002927:Cimetidine; D004155:Diphenhydramine; D004837:Epinephrine; D004910:Erythrocyte Membrane / Q000187:drug effects*; D006461:Hemolysis / Q000187:drug effects*; D006632:Histamine; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D006801:Humans; D010545:Peroxides / Q000494:pharmacology*; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000378:metabolism*; D011968:Receptors, Histamine / Q000378:metabolism*
chemical_list: D000322:Adrenergic Agonists; D000319:Adrenergic beta-Antagonists; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D010545:Peroxides; D011941:Receptors, Adrenergic; D011968:Receptors, Histamine; D002927:Cimetidine; D006632:Histamine; D004155:Diphenhydramine; D011433:Propranolol; D004837:Epinephrine